Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.7952W HIGH $62.32
Volume
1.00 M
Value Traded
36.94 M
Short % Float
14.14%
-9.87%Week
-24.56%1 Month
-19.44%3 Month
-6.5%6 Month
+32.8%5 Year
-25.82%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.00 B
EPS (TTM)
-1.45
P/E Ratio
-
Ent. Value
2.11 B
Total Shares
73.29 M
Float Shares
60.95 M
Insiders
16.82%
Institutions
96.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ELVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Enliven Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enliven Therapeutics, Inc.
202Total events
4Upcoming
43Tier-1 (high impact)
2020 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲FDA Feedback ReceivedrelcobatinibFDA Meeting
FDA alignment reached on final ENABLE-2 Phase 3 trial design
previously treated chronic myeloid leukemia (CML)source ↗
●INN Name AssignedrelcobatinibCorporate
USAN Council adopted relcobatinib as nonproprietary name for ELVN-001
chronic myeloid leukemia (CML)source ↗
▲End Of Phase 1 MeetingELVN-001FDA Meeting
FDA End-of-Phase 1 meeting reached alignment on Phase 3 design
chronic myeloid leukemia (CML)source ↗
▲Fast Track DesignationELVN-001Designation
FDA granted Fast Track designation to ELVN-001
chronic myeloid leukemia (CML)source ↗
◆Trial InitiationELVN-001Trial
Initiation of ENABLE-2 Phase 3 trial expected
chronic myeloid leukemiasource ↗
◆End Of Phase 2 MeetingELVN-001FDA Meeting
End-of-Phase 2 meeting with FDA anticipated in Q3 2026
chronic myeloid leukemia (CML)source ↗
▼Equity OfferingCorporate
Closed upsized public offering of common stock and pre-funded warrants with full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of upsized public offering of common stock and pre-funded warrants
◆Oral PresentationELVN-001Presentation
Oral presentation at EHA 2026 Congress with updated Phase 1 data for ELVN-001
chronic myeloid leukemiasource ↗
▲End Of Phase 1 MeetingELVN-001FDA Meeting
End-of-Phase 1 meeting with FDA
chronic myeloid leukemiasource ↗
▲Oral PresentationELVN-001Presentation
Positive Phase 1 data for ELVN-001 presented at EHA Congress
chronic myeloid leukemia (CML)source ↗
▲AbstractELVN-001Presentation
Abstract accepted for oral presentation at EHA 2026
chronic myeloid leukemiasource ↗
●Enrollment UpdateELVN-001Trial
Enrollment continued in 80 mg once daily expansion cohort of Phase 1b trial
chronic myeloid leukemia (CML)source ↗
◆Trial InitiationELVN-001Trial
Initiation of Phase 3 trial for ELVN-001 in CML
chronic myeloid leukemia (CML)source ↗
◆Topline ReadoutELVN-001Clinical Data
Phase 1 data update for ELVN-001 expected mid-2026
chronic myeloid leukemia (CML)source ↗
▲Topline ReadoutELVN-001Clinical Data
Positive initial Phase 1b data for ELVN-001 in CML
chronic myeloid leukemia (CML)source ↗
▲Topline ReadoutELVN-001Clinical Data
Initial Phase 1b data for ELVN-001 in CML: cumulative MMR 69% by 24 weeks
chronic myeloid leukemia (CML)source ↗
▲End Of Phase 1 MeetingELVN-001FDA Meeting
FDA End-of-Phase 1 meeting reached alignment on Phase 3 design
chronic myeloid leukemia (CML)source ↗
▲Fast Track DesignationELVN-001Designation
FDA granted Fast Track designation to ELVN-001
chronic myeloid leukemia (CML)source ↗
◆Poster PresentationELVN-001Presentation
Preliminary safety and efficacy of ELVN-001 in CML patients with atypical fusion transcripts at ASH 2025
chronic myeloid leukemia (CML) with atypical fusion transcriptssource ↗
▲Enrollment CompleteELVN-001Trial
Completed enrollment of randomized Phase 1b cohorts of ENABLE trial
chronic myeloid leukemia (CML)source ↗
◆Oral PresentationELVN-001Presentation
Oral presentation of ENABLE Phase 1a/1b data for ELVN-001 at SOHO 2025
Chronic Myeloid Leukemiasource ↗
◆Poster PresentationELVN-001Presentation
Poster presentation of ENABLE Phase 1a/1b data for ELVN-001 at SOHO 2025
Chronic Myeloid Leukemiasource ↗
▼Equity OfferingCorporate
Public offering generating gross proceeds of approximately $230 million
▼Equity OfferingCorporate
Closed underwritten public offering of common stock and pre-funded warrants, including full exercise of underwriters' option
◆Equity OfferingCorporate
Announced proposed public offering of $200 million common stock and pre-funded warrants
◆Oral PresentationELVN-001Presentation
Oral presentation of updated Phase 1 data at EHA 2025 Congress
chronic myeloid leukemia (CML)source ↗
▲Topline ReadoutELVN-001Clinical Data
Updated positive Phase 1 data announced
chronic myeloid leukemia (CML)source ↗
▲Oral PresentationELVN-001Presentation
Oral presentation of updated Phase 1 data for ELVN-001 at EHA Congress
chronic myeloid leukemia (CML)source ↗
▲Topline ReadoutELVN-001Clinical Data
Updated Phase 1 data for ELVN-001 announced
chronic myeloid leukemia (CML)source ↗
◆Oral PresentationPresentation
TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHA
▲Trial InitiationELVN-002Trial
First patient dosed in Phase 1 exploratory cohort of ELVN-002 in combination with trastuzumab deruxtecan
HER2+ colorectal cancersource ↗
◆Poster PresentationELVN-002Presentation
Poster presentation on ELVN-002 at AACR 2025
HER2-positive cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How ELVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-09 | ELVN-001 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$567M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 41%
Small Cap(rank 271 of 660)
Percentile Rank
Enliven Therapeutics, Inc. faces pipeline headwinds (39/100), with $873M risk-adjusted pipeline value, led by ELVN-002 in HER2 Mutant Non-small Cell Lung Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVN-002 Small moleculeNCT05650879 | HER2 Mutant Non-small Cell Lung Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 198 | Jul 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ELVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ELVN-001 Fast Track | chronic myeloid leukemia (CML) | Phase 1 | 2026-08-05 | 61% overall major molecular response (MMR); 48% MMR achievement by 24 weeks in the 80 mg once daily (QD) Phase 1b cohort; 67% overall MMR in earlier-line patients; 55% achieving MMR by 24 weeks among patients with one or two prior unique tyrosine kinase inhibitors (TKIs)Read More | Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Garland J. ScottDirector | Option | 13,000 13,000 held | $15.47 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 6.4 % (3.2 %) | 343.91 M | 6.78 M | -14.86% ( -1.18 M) |
ELVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELVN ranks across every disease it competes in
Competitive Position is a premium feature
See how ELVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELVN News
ELVNEnliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven Therapeutics has announced that it has reached an agreement with the FDA on the design of the ENABLE-2 Phase 3 trial for relcobatinib, aimed at patients with previously treated chronic myeloid leukemia. The trial is set to enroll around 450 adults and will compare relcobatinib to second-generation TKIs. The company is on track to initiate the trial by the end of 2026.
Read more →ELVNEnliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor conferences. These include the Wells Fargo 21st Annual Healthcare Conference, the Baird 2026 Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. The company aims to showcase its focus on small molecule therapeutics and its commitment to addressing unmet medical needs.
Read more →ELVNEnliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Enliven Therapeutics announced its participation in the Society of Hematologic Oncology (SOHO) Annual Meeting, where it will present data from the ENABLE Phase 1 trial of ELVN-001. This trial focuses on patients with previously treated chronic myeloid leukemia (CML). The presentations will include both an oral and a poster session, showcasing the potential of ELVN-001 as a targeted therapy.
Read more →ELVNEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported promising Phase 1 clinical results for ELVN-001 in chronic myeloid leukemia (CML), showing a 61% major molecular response rate. The company has also aligned with the FDA on key components for the upcoming Phase 3 ENABLE-2 trial. Financially, Enliven holds $895 million, ensuring operational stability into 2030.
Read more →ELVNEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics has successfully closed an upsized public offering of 10,533,334 shares of common stock, generating approximately $460 million in gross proceeds. This offering included the full exercise of the underwriters' option to purchase additional shares. The company aims to use these funds to further its development of small molecule therapeutics.
Read more →ELVN▲ +14.3%on this newsshared move
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics has announced the pricing of an upsized public offering, selling 8,933,334 shares of common stock at $37.50 per share, along with pre-funded warrants. The offering is expected to raise around $400 million and is set to close on June 15, 2026, pending customary conditions. The company aims to address unmet medical needs through its therapeutics.
Read more →ELVN▲ +14.3%on this newsshared move
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics has announced a proposed public offering of $250 million in common stock, along with pre-funded warrants. The offering is managed by major financial institutions and is subject to market conditions. Enliven aims to address unmet medical needs through its innovative therapeutic approaches. However, the completion and terms of the offering remain uncertain.
Read more →ELVN▲ +9.1%on this news· ran to +25% by day 1shared move
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Enliven Therapeutics has announced positive updates from its Phase 1 ENABLE trial for ELVN-001, showing significant major molecular response (MMR) rates in chronic myeloid leukemia patients. The FDA has aligned with the company on the recommended dose for the upcoming Phase 3 ENABLE-2 trial, which will target patients previously treated with tyrosine kinase inhibitors. The trial demonstrated a favorable safety profile, supporting the potential of ELVN-001 as a new treatment option.
Read more →ELVNEnliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven Therapeutics will host a webcast on June 11, 2026, to discuss updated data from the Phase 1 ENABLE trial for ELVN-001 in chronic myeloid leukemia patients. The data will be presented at the EHA 2026 Congress in Stockholm. The trial evaluates ELVN-001's efficacy and safety, particularly against the T315I mutation.
Read more →ELVN▲ +6.8%on this news
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated...
Enliven Therapeutics has announced that it will present additional positive data from its Phase 1 ENABLE clinical trial for ELVN-001 in patients with chronic myeloid leukemia (CML) at the EHA 2026 Congress. Notably, the updated data showcases a cumulative MMR rate of 47% with notable safety and tolerability. The presentation will detail findings from an ongoing trial which targets the BCR::ABL1 gene fusion in previously treated patients. The Congress presentation is scheduled for June 11, 2026, in Stockholm, Sweden.
Read more →ELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported its first quarter financial results for 2026, highlighting a strong cash position of $452 million that is expected to support operations until mid-2029. The company is preparing to initiate the Phase 3 ENABLE-2 trial for its lead candidate, ELVN-001, in the second half of 2026, following positive Phase 1b data. Despite a net loss of $23.6 million, the company remains optimistic about its future prospects in chronic myeloid leukemia treatment.
Read more →ELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Enliven Therapeutics reported positive initial data from its Phase 1b trial of ELVN-001 for chronic myeloid leukemia (CML). The company plans to initiate the Phase 3 ENABLE-2 pivotal trial in the second half of 2026. With a strong financial position, Enliven aims to demonstrate ELVN-001's potential as a leading treatment option for CML patients.
Read more →ELVNEnliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Enliven Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will be webcast live, allowing investors to access the discussion online. Enliven focuses on developing small molecule therapeutics aimed at improving patient outcomes.
Read more →ELVN▲ +50.3%on this news· ran to +68% by day 1
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics has reported promising initial data from its ongoing Phase 1b ENABLE trial for ELVN-001, a treatment for chronic myeloid leukemia (CML). The data shows a 69% cumulative major molecular response (MMR) rate by 24 weeks, indicating potential effectiveness. The company is preparing for regulatory interactions with the FDA to support the initiation of a Phase 3 trial by the second half of 2026. The results reinforce ELVN-001's positioning as a potentially best-in-class treatment option.
Read more →ELVNEnliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics has appointed Scott Garland to its Board of Directors as it prepares for a pivotal Phase 3 trial of ELVN-001 in chronic myeloid leukemia. The company aims to transition towards commercialization following positive clinical data reported in 2025. Andrew Phillips has stepped down from the Board, marking a shift in leadership as Enliven focuses on late-stage development.
Read more →ELVN▼ -10.2%on this news
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics has granted an inducement stock option to its new CEO, Richard Fair, for 875,000 shares at an exercise price of $18.77. The option will vest over time, rewarding Fair for his continued service. This move is part of Enliven's strategy to enhance leadership and drive its precision oncology initiatives.
Read more →ELVN▼ -6.9%on this newsshared move
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Enliven Therapeutics has appointed Rick Fair as its new CEO, effective December 11, 2025. Fair brings over 25 years of experience in product development, particularly in oncology and hematology. The leadership change aims to enhance the company's focus on its pivotal Phase 3 trial for ELVN-001 in chronic myeloid leukemia and advance its early pipeline assets.
Read more →ELVNEnliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported its third quarter financial results, highlighting the completion of enrollment for the Phase 1b cohorts of the ENABLE trial for ELVN-001 in chronic myeloid leukemia (CML). The company is on track to initiate a pivotal Phase 3 trial in 2026, supported by a strong financial position with $478 million available. The CML community has shown positive validation for ELVN-001, which targets the BCR::ABL gene fusion.
Read more →About Enliven Therapeutics, Inc.
Headquarters205 PARK ROAD, BURLINGAME, CA, 94010
BIOPHARMAWATCH ELITE PLUS
Trade the next ELVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime